In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. Celastrol was recognized as a Myb inhibitor that suppressed C/EBPβ action https://abbv-744-in-the-treatment68024.blogacep.com/37134403/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc